Total submissions: 15
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000083224 | SCV000244409 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2015-08-10 | reviewed by expert panel | curation | IARC class based on posterior probability from multifactorial likelihood analysis, thresholds for class as per Plon et al. 2008 (PMID: 18951446). Class 5 based on posterior probability = 0.99 |
Invitae | RCV000049081 | SCV000077094 | likely pathogenic | Hereditary breast ovarian cancer syndrome | 2023-09-10 | criteria provided, single submitter | clinical testing | This sequence change replaces leucine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 22 of the BRCA1 protein (p.Leu22Ser). This variant is not present in population databases (gnomAD no frequency). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Experimental studies have shown that this missense change affects BRCA1 function (PMID: 21990134, 25823446, 30209399). Advanced modeling performed at Invitae incorporating data from internal and/or published experimental studies (PMID: 30209399) indicates that this missense variant is expected to disrupt BRCA1 function. ClinVar contains an entry for this variant (Variation ID: 55656). This missense change has been observed in individual(s) with breast and/or ovarian cancer (PMID: 9609997, 19543972, 25452441, 28888541, 30339520, 32438681). |
Ambry Genetics | RCV000162704 | SCV000213164 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2023-04-28 | criteria provided, single submitter | clinical testing | The p.L22S variant (also known as c.65T>C), located in coding exon 1 of the BRCA1 gene, results from a T to C substitution at nucleotide position 65. The leucine at codon 22 is replaced by serine, an amino acid with dissimilar properties. This variant has been reported in Japanese, Ashkenazi Jewish, Brazilian, German, Norwegian, and Italian HBOC families (Katagiri T et al. J. Hum. Genet. 1998;43:42-8; Sweet K et al. Breast Cancer Res. Treat. 2010 Feb;119:737–43; Fernandes GC et al. Oncotarget, 2016 Dec;7:80465-80481; Heramb C et al. Hered Cancer Clin Pract, 2018 Jan;16:3; Rebbeck TR et al. Hum Mutat. 2018 May;39(5):593-620; Palmero EI et al. Sci Rep, 2018 Jun;8:9188). This alteration has been classified as definitely pathogenic (p>0.99) by multifactorial analysis, which integrates the following lines of evidence to produce a quantitative likelihood of pathogenicity: in silico prediction models, segregation with disease, tumor characteristics, and mutation co-occurrence (Easton DF et al. Am. J. Hum. Genet. 2007 Nov;81:873-83; Lindor NM et al. Hum. Mutat. 2012 Jan;33:8-21; Vallee MP et al. Hum. Mutat. 2012 Jan;33:22-8). One functional study found that this nucleotide substitution is deleterious in a high throughput genome editing haploid cell survival assay (Findlay GM et al. Nature, 2018 10;562:217-222). Of note, this alteration is also designated as 184T>C in published literature. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the majority of available evidence to date, this variant is likely to be pathogenic. |
Counsyl | RCV000083224 | SCV000220976 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2014-12-22 | criteria provided, single submitter | literature only | |
Consortium of Investigators of Modifiers of BRCA1/2 |
RCV000083224 | SCV000326372 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2015-10-02 | criteria provided, single submitter | clinical testing | |
Department of Medical Genetics, |
RCV000083224 | SCV000564345 | likely pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2015-07-01 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000479212 | SCV000568441 | likely pathogenic | not provided | 2023-09-20 | criteria provided, single submitter | clinical testing | Published functional studies suggest a damaging effect based on E3 ubiquitin ligase ability, HDR activity, colony size, and liquid medium function, while other functional assays demonstrated BARD1 binding, spot formation, and yeast localization comparable to wild-type (Starita et al., 2015; Thouvenot et al., 2016; Findlay et al., 2018; Starita et al., 2018); Observed in individuals with a personal and/or family history of breast, ovarian, and/or pancreatic cancer (Katagiri et al., 1998; Sweet et al., 2010; Couch et al., 2015; Fernandes et al., 2016; Pilato et al., 2016; Lilyquist et al., 2017; Santonocito et al., 2020; Lowery et al., 2018; Hovland et al., 2022); Multifactorial studies suggest this variant is associated with breast and ovarian cancer (Sweet et al., 2010; Lindor et al., 2012; Valle et al., 2012); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Also known as 184T>C; This variant is associated with the following publications: (PMID: 27225819, 25452441, 18951461, 24489791, 19543972, 25525159, 21990165, 24281179, 22753008, 9609997, 27272900, 25823446, 28408614, 27741520, 29339979, 29506128, 29907814, 29446198, 30219179, 30209399, 33087888, Paquette[article]2021, 35659930, 34572941, 34906479, 24389207, 20104584, 35534113, 34981296, 28888541, 32438681, 21990134) |
Color Diagnostics, |
RCV000162704 | SCV000912062 | pathogenic | Hereditary cancer-predisposing syndrome | 2021-06-01 | criteria provided, single submitter | clinical testing | This missense variant replaces leucine with serine at codon 22 of the BRCA1 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Functional studies have shown that this variant results in loss of homology-directed recombination activity of BRCA1 protein (PMID: 25823446, 30219179, 30696104) and disrupts BARD1 binding activity (PMID: 30696104). This variant has been reported to cause loss of BRCA1 function in a haploid cell proliferation assay (PMID: 30209399). This variant has been reported in multiple individuals affected with breast and/or ovarian cancer (PMID: 9609997, 19543972, 27741520, 29907814, 32380732, 32438681) and pancreatic cancer (PMID: 29506128). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Pathogenic. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000049081 | SCV000916786 | likely pathogenic | Hereditary breast ovarian cancer syndrome | 2017-12-14 | criteria provided, single submitter | clinical testing | Variant summary: The BRCA1 c.65T>C (p.Leu22Ser) variant involves the alteration of a conserved nucleotide located in the Zinc finger, RING/FYVE/PHD-type (InterPro). 5/5 in silico tools predict a damaging outcome for this variant. This variant is absent in 245708 control chromosomes, and has been reported in numerous affected individuals in the literature. Additionally, functional evidence has shown the variant to result in reduced HDR levels (Starita_2015). In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic. Taken together, this variant is classified as likely pathogenic. |
Sema4, |
RCV000162704 | SCV002537882 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2021-06-17 | criteria provided, single submitter | curation | |
Laboratory of Medical Genetics Unit, |
RCV003313774 | SCV004012925 | likely pathogenic | Infant-type hemispheric glioma | 2021-11-05 | criteria provided, single submitter | research | |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000479212 | SCV004219470 | pathogenic | not provided | 2022-12-16 | criteria provided, single submitter | clinical testing | In the published literature, the variant has been reported as being pathogenic in the published literature (PMID: 19543972 (2010), 21990134 (2012), and 21990165 (2012)). Internal analysis of published breast and ovarian cancer cases revealed an enrichment of the variant in cases compared to general population controls (PMID: 9609997 (1998), 25452441 (2015), and 29907814 (2018)). Comprehensive functional studies indicated that this variant is damaging to E3 ubiquitin-ligase activity of the BRCA1 protein (PMID: 25823446 (2015)), while another study utilizing a yeast model yielded inconclusive predictions on the effect of the variant on BRCA1 protein function (PMID: 27272900 (2016)). Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is damaging. Based on the available information, this variant is classified as pathogenic. |
Sharing Clinical Reports Project |
RCV000083224 | SCV000115298 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 1 | 2009-10-22 | no assertion criteria provided | clinical testing | |
Breast Cancer Information Core |
RCV000083224 | SCV000144166 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 1 | 2004-11-25 | no assertion criteria provided | clinical testing | |
Brotman Baty Institute, |
RCV000083224 | SCV001242257 | not provided | Breast-ovarian cancer, familial, susceptibility to, 1 | no assertion provided | in vitro |